You are seeing a free-to-access but limited selection of the activity Altmetric has collected about this research output.
Click here to find out more.
X Demographics
Mendeley readers
Attention Score in Context
| Title |
Efficacy and safety of secukinumab, a fully human anti-interleukin-17A monoclonal antibody, in patients with moderate-to-severe psoriatic arthritis: a 24-week, randomised, double-blind, placebo-controlled, phase II proof-of-concept trial
|
|---|---|
| Published in |
Annals of the Rheumatic Diseases, January 2013
|
| DOI | 10.1136/annrheumdis-2012-202646 |
| Pubmed ID | |
| Authors |
Iain B McInnes, Joachim Sieper, Jürgen Braun, Paul Emery, Désirée van der Heijde, John D Isaacs, Georg Dahmen, Jürgen Wollenhaupt, Hendrik Schulze-Koops, Joseph Kogan, Shenglin Ma, Martin M Schumacher, Arthur P Bertolino, Wolfgang Hueber, Paul P Tak |
| Abstract |
To evaluate the efficacy and safety of secukinumab, a fully human, anti-interleukin (IL)-17A monoclonal antibody, in patients with psoriatic arthritis (PsA). |
X Demographics
The data shown below were collected from the profile of 1 X user who shared this research output. Click here to find out more about how the information was compiled.
Geographical breakdown
| Country | Count | As % |
|---|---|---|
| Australia | 1 | 100% |
Demographic breakdown
| Type | Count | As % |
|---|---|---|
| Scientists | 1 | 100% |
Mendeley readers
The data shown below were compiled from readership statistics for 243 Mendeley readers of this research output. Click here to see the associated Mendeley record.
Geographical breakdown
| Country | Count | As % |
|---|---|---|
| Brazil | 2 | <1% |
| Germany | 1 | <1% |
| Ireland | 1 | <1% |
| United Kingdom | 1 | <1% |
| Russia | 1 | <1% |
| Japan | 1 | <1% |
| Unknown | 236 | 97% |
Demographic breakdown
| Readers by professional status | Count | As % |
|---|---|---|
| Researcher | 40 | 16% |
| Student > Ph. D. Student | 31 | 13% |
| Student > Master | 31 | 13% |
| Other | 26 | 11% |
| Student > Bachelor | 21 | 9% |
| Other | 54 | 22% |
| Unknown | 40 | 16% |
| Readers by discipline | Count | As % |
|---|---|---|
| Medicine and Dentistry | 116 | 48% |
| Agricultural and Biological Sciences | 15 | 6% |
| Pharmacology, Toxicology and Pharmaceutical Science | 12 | 5% |
| Immunology and Microbiology | 10 | 4% |
| Biochemistry, Genetics and Molecular Biology | 9 | 4% |
| Other | 30 | 12% |
| Unknown | 51 | 21% |
Attention Score in Context
This research output has an Altmetric Attention Score of 4. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 20 June 2023.
All research outputs
#6,920,783
of 22,694,633 outputs
Outputs from Annals of the Rheumatic Diseases
#3,415
of 7,193 outputs
Outputs of similar age
#77,030
of 282,817 outputs
Outputs of similar age from Annals of the Rheumatic Diseases
#48
of 96 outputs
Altmetric has tracked 22,694,633 research outputs across all sources so far. This one has received more attention than most of these and is in the 68th percentile.
So far Altmetric has tracked 7,193 research outputs from this source. They typically receive a lot more attention than average, with a mean Attention Score of 12.9. This one has gotten more attention than average, scoring higher than 51% of its peers.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 282,817 tracked outputs that were published within six weeks on either side of this one in any source. This one has gotten more attention than average, scoring higher than 71% of its contemporaries.
We're also able to compare this research output to 96 others from the same source and published within six weeks on either side of this one. This one is in the 48th percentile – i.e., 48% of its contemporaries scored the same or lower than it.